Related Experiment Video
Updated: Oct 1, 2025

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Hydrochlorothiazide use is associated with the risk of cutaneous and lip squamous cell carcinoma: A systematic review
Ana Cláudia de Macedo Andrade1,2, Fernanda Aragão Felix3,4, Glória Maria França3,4
1Federal University of Rio Grande of Norte, Natal-RN, Brazil. anaclaudia2008@hotmail.com.
Purpose:
The aim of this study is to investigate the association between hydrochlorothiazide (HCTZ) use and the risk of cutaneous and lip squamous cell carcinoma development.
Methodology:
We performed a systematic review and meta-analysis of case-control studies. We searched the Cochrane Library, PubMed, Scopus, Web of Science and LILACS. This study was registered in PROSPERO under protocol CRD42019129710. The meta-analysis was performed using the software Stata (version 12.0).
Results:
A total of 2181 published studies referring to the theme were identified, from which six were included in this systematic review. Men were more frequently affected by cutaneous and lip squamous cell carcinoma than women, with a 1.42:1 ratio. The mean age for cutaneous and lip squamous cell carcinoma development was 73.7 years. This meta-analysis demonstrated a chance of developing cutaneous and lip squamous cell carcinoma in any region of the body in hydrochlorothiazide users of 1.76-fold higher than in non-users. In addition, a risk factor of 1.80 higher (CI 95% = 1.71-1.89) of cutaneous squamous cell carcinoma in the head and neck region was observed in HCTZ users. Moreover, in the analysis of the dose used, the chance of developing squamous cell carcinoma was 3.37-fold lower when the concentration of HCTZ used was less than 50,000 mg.
Conclusions:
Our results confirm the association between the use of hydrochlorothiazide and the cutaneous and lip squamous cell carcinoma development.
Related Concept Videos
Antihypertensive Drugs: Thiazide-Class Diuretics
Hazard Ratio
For example, in a clinical trial...
Cancer Prevention
Some...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

